Mao Y

Epigenetic regulation of cell state by H2AFY governs immunogenicity in high-risk neuroblastoma.

Nagarajan D, Parracho RT, Corujo D, ..., Buschbeck M, Mao Y

J. Clin. Invest. 134 (21) - [2024-09-10; online 2024-09-10]

Loss of NEDD8 in cancer cells causes vulnerability to immune checkpoint blockade in triple-negative breast cancer.

Papakyriacou I, Kutkaite G, Rúbies Bedós M, ..., Menden MP, Mao Y

Nat Commun 15 (1) 3581 [2024-04-27; online 2024-04-27]

SciLifeLab Fellow Yumeng Mao

NEDD8 loss causes cancer vulnerability to immune checkpoint blockade in triple-negative breast cancer

Mao Y, Papakyriacou I, Kutkaite G, ..., Alford L, Menden M

- - (-) - [2024-03-25; online 2024-03-25]

Discovery and characterisation of quinazolines and 8-Azaquinazolines as NLRP3 agonists with oral bioavailability in mice.

O' Donovan DH, Baker D, Ciotta G, ..., Tang H, Valge-Archer V

Bioorg. Med. Chem. Lett. 96 (-) 129518 [2023-10-12; online 2023-10-12]

SciLifeLab Fellow Yumeng Mao

Human ovarian cancer intrinsic mechanisms regulate lymphocyte activation in response to immune checkpoint blockade.

Natoli M, Bonito N, Robinson JD, Ghaem-Maghami S, Mao Y

Cancer Immunol. Immunother. 69 (8) 1391-1401 [2020-08-00; online 2020-03-21]

SciLifeLab Fellow Yumeng Mao

Correction to: Human ovarian cancer intrinsic mechanisms regulate lymphocyte activation in response to immune checkpoint blockade.

Natoli M, Bonito N, Robinson JD, Ghaem-Maghami S, Mao Y

Cancer Immunol. Immunother. 69 (8) 1403-1408 [2020-08-00; online 2020-06-20]

The Next Generation of Pattern Recognition Receptor Agonists: Improving Response Rates in Cancer Immunotherapy.

O' Donovan DH, Mao Y, Mele DA

Current medicinal chemistry 27 (34) 5654-5674 [2019-06-30; online 2019-06-30]

SciLifeLab Fellow Yumeng Mao